RxDoctor Payments Data

William Davenport, MD

Ophthalmology · Stuart, FLNPI 1669425773

Payments from drug & device makers

$1,391in general payments, 2019–2025

Across 45 payments — averaging $30.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$487
  • Glaukos Corporation$191
  • Rayner Intraocular Lenses Limited$167
  • Alcon$158
  • Aerie Pharmaceuticals, Inc.$95
  • Bausch & Lomb Americas Inc.$63
  • plus $231 from 9 others

What the payments were for

  • Food & beverage$1,391100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,391 in reported general payments places this provider in the 40th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$463,148
Medicare patients
1,662
Services billed
3,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost84$56,766
RestasisCyclosporine27$40,805
RhopressaNetarsudil Mesylate33$24,582
Latanoprost1,008$12,445
Cyclosporine16$8,973
Brimonidine Tartrate220$8,218
VyzultaLatanoprostene Bunod16$6,956
Brinzolamide18$6,695
Travoprost28$5,941
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat285$5,635
Prednisolone Acetate167$5,498
SimbrinzaBrinzolamide/Brimonidine Tart16$5,478
Timolol Maleate255$3,191
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$3,162
Ketorolac Tromethamine111$2,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$487$97,571111 claims
Aerie Pharmaceuticals, Inc.Rhopressa$95$24,58233 claims
Bausch & Lomb Americas Inc.Vyzulta$63$6,95616 claims
AlconSimbrinza$158$5,47816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →